FDA Drug Recalls

Recalls / Class II

Class IID-0560-2022

Product

Moxifloxacin Ophthalmic Solution, USP 0.5% w/v, 3 mL bottle, Sterile, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, Made in India, NDC 65862-840-03

Brand name
Moxifloxacin
Generic name
Moxifloxacin
Active ingredient
Moxifloxacin Hydrochloride
Route
Ophthalmic
NDC
65862-840
FDA application
ANDA206242
Affected lot / code info
Lot#: CMF210001, CMF210003, CMF210004, Exp 6/2023

Why it was recalled

Failed Impurities/Degradation Specifications

Recalling firm

Firm
Aurobindo Pharma USA Inc.
Manufacturer
Aurobindo Pharma Limited
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
279 Princeton Hightstown Rd, N/A, East Windsor, New Jersey 08520-1401

Distribution

Quantity
115776 bottles
Distribution pattern
USA Nationwide

Timeline

Recall initiated
2022-01-14
FDA classified
2022-02-14
Posted by FDA
2022-02-23
Terminated
2024-07-31
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0560-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.